Navigation Links
Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Date:12/18/2007

SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled "In Vivo Barriers to Gene Delivery" was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided. The meeting served to inform the public and the scientific community that there were actual reasons that the much heralded promise of gene therapy had thus far failed to deliver. Perhaps, if the title of the meeting had been changed to "In Vivo Solutions to Gene Delivery," the scientists of Epeius Biotechnologies might have attended.

*(LOGO 72dpi: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)

2007 was a year that the 'experts' of all things targeted published a remarkable review article in Nature (Nature Reviews, Genetics, 2007, 8:573-587) entitled "Engineering Targeted Viral Vectors for Gene Therapy." Among the flotsam and jetsam of adenoviral shipwrecks, and the ruminative discourses on "Obstacles to Systemic Targeting," was an intriguing preface stating that "the first clinical trials have already begun to take place," and a brief notation that may be of considerable scientific interest. And we quote, "A third example is represented by the first and so far only targeted vector that has been tested in the clinic: the retroviral vector Rexin-G, which expresses a cytocidal dominant-negative form of cyclin G1." The article goes as far as to mention the fact that a number of clinical studies have "demonstrated the effectiveness of the vector" in the crucible of clinical medicine.

Ironically, 2007 is also the year in which the much acclaimed and heavily subsidized National Gene Vector Laboratories (NGVL) -- whose mission and "primary goal" as an academic vector product
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
2. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
3. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
5. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
9. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
10. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014  Misonix, Inc. (NASDAQ: ... designs, manufactures and markets innovative therapeutic ultrasonic instruments for ... that it will report financial results for the first ... The Company has scheduled a conference call that same ... to review the results. Interested parties ...
(Date:10/30/2014)... , Oct. 30, 2014 Boston Scientific ... participate in the 2014 Credit Suisse Annual Healthcare Conference ... , AZ.  Dan Brennan , executive vice ... about the company beginning at approximately 8:00 a.m. PT ... A live webcast of the presentation and question and ...
(Date:10/30/2014)... -- Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 30, 2014 on Thursday, November 6, 2014, after the ... president and chief executive officer, will host a conference ... Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... of the conference call can be accessed through a ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
... Aug. 20, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: ... leading China-based biotechnology company focused on researching, developing, ... the annual general meeting of shareholders of 3SBio ... at 10:00 a.m., Shenyang time, at our executive ...
... As Medicare expands a controversial "competitive" bidding program for home ... Congress have gone on record to oppose that program citing ... and impact on local jobs. "There,s a reason ... 244 economists and auction experts , and 145 members ...
Cached Medicine Technology:3SBio Inc. to Hold 2011 Annual General Meeting on September 20, 2011 2Myths and Realities About Medicare's Competitive Bidding Program for Home Medical Equipment and Services 2Myths and Realities About Medicare's Competitive Bidding Program for Home Medical Equipment and Services 3Myths and Realities About Medicare's Competitive Bidding Program for Home Medical Equipment and Services 4Myths and Realities About Medicare's Competitive Bidding Program for Home Medical Equipment and Services 5
(Date:10/30/2014)... of data from an institutional patient registry on ... control, 79 percent of tumors, for medically inoperable, ... from 2003 to 2012, according to research presented ... Thoracic Oncology. The Symposium is sponsored by the ... Society for Radiation Oncology (ASTRO), the International Association ...
(Date:10/30/2014)... WHAT: , A mathematical model developed by NIH grantees ... daily to prevent HIV infection via vaginal sex, whereas ... HIV infection via anal sex. This finding helps explain ... or PrEP, in women failed to show efficacy. Participants ... trials of Truvada and tenofovir (another antiretroviral) for HIV ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Five months ... Hodgkinson Street LLC announces new branding and a ... Street Mepham . After David Mepham’s promotion to name ... brand and website to include Mepham’s name and better ... malpractice and mediation firm, the decision to implement new ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
Breaking Medicine News(10 mins):Health News:Sustained local control for medically inoperable, early stage lung cancer patients 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 3Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3
... The Lupus Foundation of,America (LFA) is ... in grant funding,for basic, clinical, or translational ... fatal autoimmune disease. The purposes of the,studies ... novel,approaches; and develop experimental prototypes. Grants will ...
... Council (ACC) today sent a letter to FDA ... review of the safety of bisphenol A,in food ... study regarding bisphenol A is well,documented and well ... the safety and use of polycarbonate plastic and ...
... Mass., April 17 Inverness Medical,Innovations, Inc. (Amex: ... point-of-care,diagnostic products, today announced that it will release ... 2008. The Company will also host a,conference call ... date to,discuss these results and other corporate matters. ...
... They,re more disruptive than long hours, night shifts or job ... Common job-related problems such as conflicts with bosses or co-workers ... insecurity to cause poor sleep. , That,s the conclusion of ... from two surveys of about 2,300 U.S. adults who were ...
... Pennsylvania School of Medicine are developing a novel approach ... as amyotrophic lateral sclerosis (ALS), or Lou Gehrig,s disease, ... mutations have been found in a disease protein called ... of frontotemporal dementia (FTD). , We,ve created a ...
... KIRKLAND, Wash., April 17 For health reasons, Americans,in ... than they think,according to Denise Gott, Vice Chairperson of ... long term care insurance agencies.,"The sudden need for long ... "and they,re vulnerable on two fronts, not just one, ...
Cached Medicine News:Health News:Lupus Foundation of America Seeks Funding Proposals for Research Studies on Childhood Lupus, Nervous System Involvement, and More 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 3Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 24, 2008 to Discuss First Quarter 2008 Results 2Health News:Work Conflicts Can Do a Job on Your Sleep 2Health News:Penn researchers find potential in yeast for selecting Lou Gehrig's disease drugs 2Health News:Today's Working Adults Face Long Term Care 'Double Whammy,' Says Denise Gott, Spokesperson for LTC Financial Partners, LLC 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: